I wonder why Aethlon Medical, Inc. (AEMD) is going downhill in the premarket?

Will we continue down this path, and if so, why? I suspect the NASDAQ-listed shares of Centennial Resource Development, Inc. might provide a clue to the answer. As of today, there have been no new developments with regards to the company, but it continues to fall consistently as Aethlon Medical, Inc. (Nasdaq: AEMD) shares drowned 6.73% to 2.08 in the premarket session.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Discover Tomorrow's Stocks Today!

When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.

Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored

And all this shows me is that investors are all quite shaken up by Aethlon Medical, Inc. (Nasdaq: AEMD) news on December 16, 2020, that the first patient was treated in the Company’s first clinical Early Feasibility Trial testing HEMOPURIFIER in patients with chronic and/or metastatic head and neck squamous cell carcinoma.

Read More

The study is enrolling patients at UPMC Hillman Cancer Center in Pittsburgh, PA. Hemopurifier Plus Pembrolizumab in Head and Neck Cancer. I wondered whether all the anxiety was overblown.

Most Popular

Related posts